CAS Number: 503612-47-3
Therapeutic Category
Anti-Coagulant
API Technology
Synthetic
Dose Form
Oral Solids
Available Regulatory Filing
USA
Korea
Vietnam
Brazil
Europe
Indonesia
China
Innovator Brand (USA)
Eliquis
Mechanism of Action
Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development
Indication
ELIQUIS is a factor Xa inhibitor indicated:
- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
- For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
- For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.